Anti-tuberculosis

Tuberculosis continues to be one of the world’s deadliest diseases, affecting over 10 million people worldwide, and still causing 1.7 million deaths yearly. Rooted in our profound belief that the fight against TB requires commitment from private sector partners, we are working together with the Stop TB partnership, and the Global Fund to fight AIDS, Tuberculosis and Malaria (GFATM), to supply high-quality Swissmedic-approved anti-tuberculosis medicines. We are listed as an approved supplier to multiple UN/WHO agencies, GFATM, and the Global Drug Facility (GDF). We continue to expand our anti-tuberculosis product portfolio, and aim to remain a key partner in the global fight against TB.
  • Product
    Region
  • Hospital
    Isoniazid
    CH
  • Hospital
    Myambutol
    CH
  • Hospital
    Pyrazinamide
    MENA, CH
  • Hospital
    Rifampicin
    CH

Get in touch

Would you like to discuss a collaboration or partnership project? Get in touch with us at partnering@labatec.com or connect with us at one of the upcoming events.

For other enquiries, please visit our contact page.